Month: November 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5061-21-2,2-Bromo-4-butanolide,as a common compound, the synthetic route is as follows.

5061-21-2, General procedure: Anhydrous K2CO3 (5 equiv) was added to the solution of relevantamine (1 equiv) and tetrabutylammonium bromide (TBAB)(0.01 equiv) in the acetonitrile and the mixture was stirred at at0 C for 1.5 h. Then a solution of 3-bromodihydrofuran-2(3H)-one(8) or 3-bromo-5-methyldihydrofuran-2(3H)-one (9) (1 equiv)was added dropwise and stirring was continued for 12-48 h atroom temperature. After the reaction was completed, the precipitatewas filtered off and the filtrate was concentrated under vacuum.Obtained crude products were purified by columnchromatography. Reagents and conditions: 4.85mmol 2 (1.22g), 24.25mmol K2CO3 (3.35g), 0.05mmol TBAB (0.02g), 4.85mmol 8 (0.80g), 20ml MeCN, 20h; purification by column chromatography (S5); Yield 72%; yellow oil; Rf: 0.76 (S7); 1H NMR (300MHz, chloroform-d) delta ppm 1.27-1.39 (m, 2H(piperidine)) 1.54-1.65 (m, 2H(piperidine)) 2.15 (dt, J=11.41, 3.53Hz, 1H(piperidine)) 2.22-2.35 (m, 3H (piperidine)) 2.60 (td, J=11.41, 2.56Hz, 1H(CHCH)) 2.71-2.80 (m, 1H(NCHCH2CH2)) 2.95-3.02 (m, 1H(NCHCH2CH2)) 3.47-3.52 (d, 1H (CHCH)) 3.54-3.61 (t, 1H (NCH)) 4.17 (td, J=8.91, 7.82Hz, 1H(CH2CH2O)) 4.27-4.38 (m, 1H (CH2CH2O)) 7.07-7.41 (m, 10H(Ar)), ESI-MS (m/z) 336.2 [M+H]+.

As the paragraph descriping shows that 5061-21-2 is playing an increasingly important role.

Reference£º
Article; Kowalczyk, Paula; Sa?at, Kinga; Hoefner, Georg C.; Guzior, Natalia; Filipek, Barbara; Wanner, Klaus T.; Kulig, Katarzyna; Bioorganic and Medicinal Chemistry; vol. 21; 17; (2013); p. 5154 – 5167;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

19311-37-6, 3-Bromotetrahydrofuran is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a saturated aqueous solution of Na2SO3 (20.0 mL) was added 3-bromotetrahydrofuran (2.00 g, 14.83 mmol).The reaction mixture was warmed to reflux,The reaction was stirred for 24 hours,And then concentrated under reduced pressure.To the resulting residue was added ethanol (30 mL)Heating up to 50 ,Stir for 30 minutes,Instantly hot filter.The filtrate was concentrated under reduced pressure,The resulting residue was dried in vacuo to give the title compound as a white solid (1.81 g, 72.6% yield).

19311-37-6, 19311-37-6 3-Bromotetrahydrofuran 12929516, aTetrahydrofurans compound, is more and more widely used in various fields.

Reference£º
Patent; Sunshine Lake Pharma Co., Ltd.; Xi, Ning; Dai, Weilong; Li, Minxiong; Chen, Wuhong; Zhang, Tao; Hu, Haiyang; Li, Xiaobo; Liu, Jun; Wang, Tingjin; (146 pag.)CN106478651; (2017); A;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

64001-06-5, 4-((Tetrahydrofuran-2-yl)oxy)butan-1-ol is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 1 A crude product stream from a production of 1,4-butanediol carried out in accordance with WO 97/43242 was treated according to the process of the present invention at a reaction temperature of 600C and a pressure of 600 psig, a gas rate of lOOnlph and a LHSV of lhr1 over the catalyst PG85/1. The peak acetal content of the crude feed as measured by the Peak Acetal Test was 0.429wt% and that of the product was found to be 0.234wt%, indicating a 50% removal.; Example 2The reaction of Example 1 was repeated at a temperature of 7O0C. The peak acetal content of the crude feed as measured by the Peak Acetal Test was 0.429wt% and that of the product was found to be 0.212 wt%.; Example 3The reaction of Example 1 was repeated at gas rate of 25nlph. The peak acetal content of the crude feed as measured by the Peak Acetal Test was 0.429wt% and that of the product was found to be 0.252wt%.; Examples 4 to 11A 50ml bed of copper chromite catalyst PG85/1 was activated by the following procedure. The gas rate was set to give the required gas velocity in the reactor and the pressure was set to 50 psig. The gas flow was established using N2 and while the reactor was at room temperature the following procedure was commenced: the H2 concentration was increased to 0.1% and the inlet temperature was brought up to 1200C over 3 hours; the H2 was monitored at the inlet and outlet above 100C and the H2 inlet was kept at 0.1%; during the following steps it was ensured that the exotherm did not exceed 10C by reducing the H2 inlet composition if necessary and the conditions were held until the exotherm reduced; the temperature was then increased by 100C until it reached 16O0C; when at 1600C the H2 in the exit gas only differed slightly from the inlet composition; after being held for 1 hour the inlet gas H2 composition was increased to 0.2% over 1 hour and held for 2 hours; the H2 in the inlet was then increased to 0.3% for 1 hour and held for 2 hours; the H2 in the inlet was then increased to 0.4% for 1 hour and held for 2 hours; the H2 in the inlet was then increased to 0.5% and held until the H2 at the inlet equalled the H2 at the exit; the 0.5% H2 in the inlet was then maintained and the temperature increased to 1700C over 1 hour and it was ensured that the exotherm did not exceed 100C and held until H2 at the inlet equalled the H2 at the exit; the temperature was then maintained at 1700C; the H2 content at the inlet was then slowly increased to 1% over a minimum time of 1 hour and maintained until H2 at the inlet equalled the H2 at the exit; the exotherm was then monitored to keep it below 100C, by reducing H2 concentration if needed, then the H2 concentration was increased up to 5% at 1% per hour; the H2 at the inlet was increased slowly to 10% and maintained until H2 at the inlet equalled the H2 at the exit; the exotherm was monitored to keep it below 100C; the H2 at the inlet was increased to 100% while making sure the exotherm did not exceed 100C; the operating pressure was then increased and left under H2 for 4 hours before the liquid feed was turned on. EPO A crude hydrogenation product containing 0.48wt% of 2-(4-hydroxybutoxy)-tetrahydrofuran precursors Lambdavas passed over the heated reaction zone under the conditions set out in Table 1.Table 1 Example 12A further example demonstrated the present invention on a miniplant scale. A 250ml bed of copper chromite catalyst PG85/1 was activated by the method described above. The reaction conditions are set out in Table 2.Table 2 The crude hydrogenation product had a Peak Acetal of 0.46wt% following treatment this resulted in a level of 19%. The material from this miniplant was distilled via the conventional EPO distillation processes to provide 1 ,4-butanediol product that contained 0.8% 2-(4- hydiOxybutoxy)-tetrahydiOforan. This demonstrated that a high purity polymer grade 1 ,4- butanediol can be achieved in high yield., 64001-06-5

The synthetic route of 64001-06-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DAVY PROCESS TECHNOLOGY LIMITED; WO2006/37957; (2006); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.184950-35-4,(Tetrahydrofuran-3-yl)methanamine hydrochloride,as a common compound, the synthetic route is as follows.

5-butylisoxazole-3-carboxylic acid (0.50 g, 3.0 mmol), Tetrahydrofuran-3-ylmethylamine hydrochloride (0.50 g, 3.6 mmol), Triethylamine (0.36 g, 3.6 mmol) And 1-hydroxybenzotriazole (0.05 g, 0.36 mmol) Was added to chloroform (amylene added product) (20 mL). To the mixture, 1-Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (0.69 g, 3.6 mmol) was added at room temperature, After stirring overnight, And concentrated under reduced pressure. Dilute hydrochloric acid was added to the concentrate, Extracted twice with ethyl acetate. The organic layer was washed with saturated brine, After drying with anhydrous sodium sulfate, And concentrated under reduced pressure. The residue was subjected to silica gel column chromatography, Represented by the following equation N- (tetrahydrofuran-3-ylmethyl) -5-butylisoxazole-3-carboxamide (Hereinafter referred to as the present amide compound (11)) 0.28 g

184950-35-4, The synthetic route of 184950-35-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SUMITOMO CHEMICAL COMPANY LIMITED; SUMITA, YUSUKE; (264 pag.)JP2015/51963; (2015); A;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.453-20-3,3-Hydroxytetrahydrofuran,as a common compound, the synthetic route is as follows.

Example 7A; rac-4-(Tetrahydrofuran-3-yloxy)benzaldehyde 3.00 g (24.6 mmol) of 4-hydroxybenzaldehyde, 2.16 g (24.6 mmol) of 3-hydroxytetrahydrofuran and 9.67 g (36.8 mmol) of triphenylphosphine were dissolved in 100 ml of THF, and 16.0 g (36.8 mmol) of a 40% strength solution of diethyl azodicarboxylate in toluene was added a little at a time over a period of 15 min. The solution was heated under reflux for 4 h. Ethyl acetate was added after cooling, the mixture was washed with 0.5 N aqueous sodium hydroxide solution and saturated sodium chloride solution and the organic phase was dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel using the mobile phase cyclohexane/ethyl acetate (7:3).Yield: 1.80 g (38% of theory)LC-MS (Method 8): Rt=2.81 min; MS (ESIpos): m/z=193 (M+H)+ 1H-NMR (400 MHz, DMSO-d6): delta=9.87 (s, 1H); 7.87 (d, 2H); 7.12 (d, 2H); 5.17 (t, 1H); 3.92 (dd, 1H); 3.88-3.74 (m, 3H); 2.29 (m, 1H); 1.99 (m, 1H).

453-20-3, The synthetic route of 453-20-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT; US2011/21487; (2011); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.88675-24-5,Tetrahydrofuran-3-amine,as a common compound, the synthetic route is as follows.

88675-24-5, To a solution of (4S)-7-(6-methylpyridin-3-yl)-2,3,4,5-tetrahydro-1,4-methanopyrido[2,3-b][1,4]diazepine (300 mg, 1.189 mmol) in tetrahydrofuran (THF) (10 mL) triphosgene (176 mg, 0.594 mmol) was added at 0 C. After 30 min DIPEA (1.038 mL, 5.94 mmol), tetrahydrofuran-3-amine (155 mg, 1.783 mmol) was added and the reaction mixture was stirred at 70 C. for 16 h. The reaction was allowed to reach RT and then poured on cold water (50 mL) and extracted with ethyl acetate (2¡Á30 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure to yield the crude product. The crude product was purified by flash column chromatography (silica-gel: 100-200 mesh, eluent: 3% MeOH in DCM) to obtained (4S)-7-(6-methylpyridin-3-yl)-N-(tetrahydrofuran-3-yl)-3,4-dihydro-1,4-methano pyrido[2,3-b][1,4]diazepine-5(2H)-carboxamide (137.1 mg, 0.371 mmol, 31.2% yield) as an off white solid. (TLC system: Rf: 0.2, 5% MeOH-DCM), LCMS (m/z): 366.2 [M+H]+. 1H NMR (400 MHz, CDCl3): delta ppm 10.76 (br t, J=6.80 Hz, 1H), 8.89 (s, 1H), 7.99 (dd, J=8.22, 2.08 Hz, 1H), 7.54 (d, J=7.89 Hz, 1H), 7.30-7.21 (m, 2H), 5.62 (dd, J=5.81, 2.96 Hz, 1H), 4.56 (br dd, J=4.82, 1.97 Hz, 1H), 4.01-3.75 (m, 4H), 3.30-3.06 (m, 3H), 2.99-2.91 (m, 1H), 2.62 (s, 3H), 2.39-2.21 (m, 2H), 2.07-1.85 (m, 2H).

As the paragraph descriping shows that 88675-24-5 is playing an increasingly important role.

Reference£º
Patent; BLUM, Charles A.; Caldwell, Richard Dana; Casaubon, Rebecca; Disch, Jeremy S.; Fox, Ryan Michael; Koppetsch, Karsten; Miller, William Henry; NG, Pui Yee; Oalmann, Christopher; Perni, Robert B.; Szczepankiewicz, Bruce G.; White, Brian; US2015/152108; (2015); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.124391-75-9,(S)-(Tetrahydrofuran-3-yl)methanol,as a common compound, the synthetic route is as follows.

To a cooled (0¡ãC) solution of (tetrahydrofuran-3-yl)methanol (3.0 mL) and triethylamine (5.7 mL) in dichloromethane (30 mL) is added methanesulfonyl chloride (3.1 mL). The mixture is stirred for 12 hours at room temperature. After cooling to 0¡ãC triethylamine (1 .3 mL) and methanesulfonyl chloride (0.7 mL) are added and the mixture is stirred for 12 hours at room temperature. The mixture is partitioned between dichloromethane and saturated aqueous NaHCO3 solution and stirred vigorously for 30 minutes. The organic phase is separated, washed with brine and dried (MgSO4). The solvent is evaporated to give the title compound. Yield: 5.6 g; TLC: rf = 0.35 (silicagel, cyclohexane/ethyl acetate 1 :1 ); Mass spectrum (EST): m/z = 181 [M+H]+., 124391-75-9

The synthetic route of 124391-75-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; ECKHARDT, Matthias; FRATTINI, Sara; HAMPRECHT, Dieter; HIMMELSBACH, Frank; LANGKOPF, Elke; LINGARD, Iain; PETERS, Stefan; WAGNER, Holger; WO2013/144098; (2013); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

184950-35-4, (Tetrahydrofuran-3-yl)methanamine hydrochloride is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Production Example 145 (0465) 5-(Hydroxyphenylmethyl)isoxazole-3-carboxylic acid (2.56 g, 10.4 mmol), tetrahydrofuran-3-ylmethylamine hydrochloride (1.77 g, 13.0 mmol), triethylamine (1.31 g, 13.0 mmol) and 1-hydroxybenzotriazole (0.18 g, 1.3 mmol) were added to chloroform (amylene addition product) (13 mL). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (2. 42 g, 13.0 mmol) was added to the mixture at room temperature, and the mixture was stirred overnight and then concentrated under reduced pressure. Dilute hydrochloric acid was added to the concentrate, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated saline water, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was applied to a silica gel column chromatography to obtain 2.78 g of N-(tetrahydrofuran-3-ylmethyl)-5-(1-phenyl-1-hydroxymethyl) isoxazole-3-carboxamide (hereinafter, referred to as Compound of Present Invention (152)) represented by the following formula. 1H-NMR(CDCl3, TMS, delta(ppm)):1.64-1.67(1H, m), 2.03-2.12(1H, m), 2.53-2.59(1H, m), 3.43-3.46(2H, m), 3.58(1H, dd), 3.76(1H, dd), 3.84(1H, dd), 3.89-3.91(1H, m), 5.97(1H, s), 6.61(1H, s), 6.95(1H, s), 7.37-7.45(5H, m)., 184950-35-4

184950-35-4 (Tetrahydrofuran-3-yl)methanamine hydrochloride 17750392, aTetrahydrofurans compound, is more and more widely used in various fields.

Reference£º
Patent; Sumitomo Chemical Company, Limited; MITSUDERA, Hiromasa; AWASAGUCHI, Kenichiro; AWANO, Tomotsugu; UJIHARA, Kazuya; EP2952096; (2015); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

184950-35-4, (Tetrahydrofuran-3-yl)methanamine hydrochloride is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Production Example 108 (0424) Tetrahydrofuran-3-ylmethylamine hydrochloride (0.16 g, 1.2 mmol) and triethylamine (0.12 g, 1.2 mmol) were added to chloroform (amylene addition product) (5 mL). 5-(3-Phenylbenzyloxymethyl)isoxazole-3-carboxylic acid (0.25 g, 0.8 mmol), 1-hydroxybenzotriazole (0.01 g, 0.08 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.22 g, 1.2 mmol) were added to the mixture at room temperature, and the mixture was stirred for 3 hours. Then, dilute hydrochloric acid was added thereto, and the mixture was extracted twice with chloroform. The organic layer was washed with a saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was applied to a silica gel column chromatography to obtain 0.21 g of N-(tetrahydrofuran-3-ylmethyl)-5-(3-phenylbenzyloxymethyl)i soxazole-3-carboxamide (hereinafter, referred to as Compound of Present Invention (113)) represented by the following formula. 1H-NMR(CDCl3, TMS, delta(ppm)): 1.63-1.71(1H, m), 2.04-2.13(1H, m), 2.52-2.63(1H, m), 3.45-3.48(2H, m), 3:57-3.61(1H, m), 3.74-3.79 (1H, m), 3.84-3.94 (2H, m), 4.68(2H, s), 4.69 (2H, s), 6.74(1H, s), 6.95(1H, br s), 7.32-7.38(2H, m), 7.43-7.47(3H, m), 7.55-7.61(4H, m), 184950-35-4

As the paragraph descriping shows that 184950-35-4 is playing an increasingly important role.

Reference£º
Patent; Sumitomo Chemical Company, Limited; MITSUDERA, Hiromasa; AWASAGUCHI, Kenichiro; AWANO, Tomotsugu; UJIHARA, Kazuya; EP2952096; (2015); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem